Psychopharmacology in autism: An update

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 18-28

  Canitano, Roberto ^a   Scandurra, Valeria ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Autism; Children and adolescents; Pervasive developmental disorders; Psychopharmacology

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; OLANZAPINE; PENTOXIFYLLINE; PIRACETAM; PLACEBO; RISPERIDONE; SECRETIN; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; AGITATION; ANOREXIA; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; BEHAVIOR DISORDER; BEHAVIOR THERAPY; COMMUNICATION DISORDER; COMPULSION; CONCENTRATION LOSS; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSKINESIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; IMPULSIVENESS; INCREASED APPETITE; INFORMATION RETRIEVAL; INSOMNIA; LANGUAGE DISABILITY; LOW DRUG DOSE; NEUROBIOLOGY; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PHYSICAL ACTIVITY; PRESYNCOPE; PSYCHOPHARMACOLOGY; RELIABILITY; REVIEW; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; STEREOTYPY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOPHARMACOLOGY;

EID: 78650942464     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.10.015     Document Type: Review

References (79)

1. Akhondzadeh S., Tajdar H., Mohammadi M.R., Mohammadi M., Nouroozinejad G.H., Shabstari O.L., et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008, 39:237-245. Epub 2007 Oct 11.
2. Akhondzadeh S., Fallah J., Mohammadi M.R., Imani R., et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:32-36. Epub 2009 Sep 20, 2009.
3. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89:485-491.
4. Aman M.G., Lam K.S., Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 2003, 33:527-534.
5. Aman M.G., Hollway J.A., McDougle C.J., Scahill L., Tierney E., McCracken J.T., et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 2008, 18:227-236.
6. Aman M.G., Farmer C.A., Hollway J., Arnold L.E. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17:713-738.
7. Aman M.G., McDougle C.J., Scahill L., Handen B., et al. The Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009, 12:1143-1154.
8. American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders 1994, DSM-IV, Washington, DC. 4th edition.
9. Anagnostou E., Esposito K., Soorya L., Chaplin W., Wasserman S., Hollander E. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol 2006, 26:444-446.
10. Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007, 61:545-550. Epub 2006 May 30.
11. Arnold E., Aman M., Cook A., Witwer A., et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006, 45:1196-1205.
12. Arnold L.E., Farmer C., Kraemer H.C., Davies M., Witwer A., Chuang S., et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010, 20:83-93.
13. Baghdadli A., Pascal C., Grisi S., Aussilloux C. Risk factors for self-injurious behaviours among 222 young children with autistic disorders. J Intellect Disabil Res 2003, 47:622-627.
14. Bartz J.A., Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res 2008, 170:451-462.
15. Belsito K.M., Law P.A., Kirk K.S., Landa R.J., Zimmerman A.W. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001, 31:175-181.
16. Bethea T.C., Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry 2007, 6:521-537.
17. Bodfish J.W., Symons F.J., Parker D.E., Lewis M.H. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 2000, 30:237-243.
18. Canitano R. Epilepsy in autism spectrum disorders. Eur Child Adolesc Psychiatry 2007, 16:61-66. Epub 2006 Aug 24.
19. Canitano R., Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008, 4:723-730.
20. Childs J.A., Blair J.L. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs 1997, 29:244-248.
21. Cook E.H., Leventhal B.L. The serotonin system in autism. Curr Opin Pediatr 1996, 8:348-354.
22. Dawson G. Early behavioral intervention, brain plasticity, and the prevention of autism spectrum disorder. Dev Psychopathol 2008, 20:775-803.
23. Di Martino A., Tuchman R. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr Neurol 2001, 25:199-207.
24. Ettinger A.B. Psychotropic effects of antiepileptic drugs. Neurology 2006, 67:1916-1925.
25. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009, 65:591-598.
26. Gencer O.F., Neslihan I.E., Miral S., Baykara B., Baykara A., Dirik E. Comparison of long term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. Eur Child Adolesc Psychiatry 2008, 17:217-225.
27. Ghuman J.K., Aman M.G., Lecavalier L., et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol 2009, 19:329-339.
28. ECDEU assessment manual for psychopharmacology: Publication ADM 76-338 1976, 218-222. US Department of Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
29. Hellings J.A., Weckbaugh M., Nickel E.J., Cain S.E., Zarcone J.R., Reese R.M., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005, 15:682-692.
30. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
31. Hollander E., Soorya L., Wasserman S., Esposito K., Chaplin W., Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Neuropsychopharmacol 2005, 9:209-213.
32. Hollander W., Wasserman S., Swanson E., Chaplin W., Schapiro M., Zagursky K., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006, 16:541-548.
33. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007, 4:498-503. Epub 2006 Aug 14.
34. Hollander E., Chaplin W., Soorya L., Wasserman S., Novotny S., Rusoff J., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010, 35:990-998. Epub 2009 Dec 9.
35. Jahromi L.B., Kasari C.L., McCracken J.T., Lee L.S., Aman M.G., McDougle C.J., et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2009, 39:395-404.
36. King B.H., Wright D.M., Handen B.L., Sikich L., Zimmerman A.W., McMahon W., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:658-665.
37. King B.H., Hollander E., Sikich L., McCracken J.T., Scahill L., Bregman J.D., et al. STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66:583-590.
38. Kolevzon A., Mathewson K.A., Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 2006, 67:407-414.
39. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006, 36:1101-1114.
40. Levy S.E., Hyman S.L. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17:803-820.
41. Lord C., Rutter M., Goode S., et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 1989, 19(2):185-212.
42. Luby J., Mrakotsky C., Stalets M.M., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006, 16:575-587.
43. Malone R.P., Maislin G., Choudhury M.A., Gifford C., Delaney A. Risperidone treatment in children and adolescents with autism: short and long term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002, 41:140-147.
44. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
45. Masi G. Pharmacotherapy of pervasive developmental disorders. Handbook of child and adolescent psychopharmacology 2006, 346. Informa Healthcare, Abingdon UK. B. Vitiello, G. Masi, D. Marazziti (Eds.).
46. Matson J.L., Hess J.A. Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Research in Autism Spectrum Disorders 2010, Epub ahead of print 20 May.
47. Matson J.L., Nebel Schwalm M. Assessing challenging behaviours in children with autism spectrum disorders: a review. Res Dev Disabil 2007, 28:367-379.
48. Matson J.L., Neal D., Fodstad J.C., Hess J.A. The relation of social behaviours and challenging behaviours in infants and toddlers with autism spectrum disorders. Dev Neurorehabil 2010, 13:164-169.
49. McCracken J., McGough J., Shah B., Cronin P., Hong D., Aman M.G., Cronin P., Hong D., Aman M.G., et al. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321. 2002.
50. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005, 162:1142-1148. 2005.
51. McDougle C.J., Stigler K.A., Erickson C.A., Posey D. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008, 69(Suppl 4):15-20.
52. Mohammadi M.R., Akhondzadeh S. Autism spectrum disorders: etiology and pharmacotherapy. Curr Drug Ther 2007, 2:97-103.
53. Mundy P., Delgado C., Block J., Venezia M., Hogan A., Seibert J. A manual for the abridged Early Social Communication Scales (ESCS) 2003, University of Miami, FL, Coral Gables.
54. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006, 21:450-455.
55. Niederhofer H., Staffen W., Mair A. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Hum Psychopharmacol 2003, 18:389-393.
56. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
57. Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007, 37:367-373.
58. Parikh M.S., Kolevzon A., Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008, 2:157-178.
59. Plioplys A.V. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 1994, 148:220-222.
60. Posey D.J., Erickson C.A., McDougle C.J. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008, 4:787-790.
61. Remington G., Sloman L., Konstantareas M., Parker K., Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001, 21:440-444.
62. Richler J., Bishop S.L., Kleinke J.R., Lord C. Restricted and repetitive behaviors in young children with autism spectrum disorders. J Autism Dev Disord 2007, 37:73-85. Epub 2006 Dec 30.
63. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005, 62:1266-1274. RUPPAN (Research Units on Pediatric Psychopharmacology Autism Network).
64. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6months. Am J Psychiatry 2005, 162:1361-1369. RUPPAN (Research Units on Pediatric Psychopharmacology Autism Network).
65. Scahill L., McDougle C.J., Williams S.K., Dimitropoulos A., Aman M.G., et al. RUPPAN. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Amer Acad Child Adolesc Psychiatry 2006, 45:1114-1123.
66. Schopler E., Reichler R.J., DeVellis R.F., Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980, 10:91-103.
67. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
68. Soorya L., Kiarashi J., Hollander E. Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17:753-771. viii.
69. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil 2005, 26:87-97.
70. Swanson J., Nolan W., Pelham W.E. SNAP rating scale. Educational resource in Education, ERIC 1982.
71. Troost P.W., Lahuis B.E., Steenhuis M.P., et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005, 44:1137-1144.
72. Tuchman R. AEDs and psychotropic drugs in children with autism and epilepsy. Ment Retard Dev Disabil Res Rev 2004, 10:135-138.
73. Tuchman R., Moshé S.L., Rapin I. Convulsing toward the pathophysiology of autism. Brain Dev 2009, 31:95-103.
74. Tuchman R., Alessandri M., Cuccaro M. Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment. Brain Dev 2010, 9:719-730.
75. Turner M. Repetitive behaviour in autism: a review of psychological research. J Child Psychol Psychiatry 1999, 40:839-849.
76. Wasserman S., Iyengar R., Chaplin W.F., Watner D., Waldoks S.E., Anagnostou E., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21:363-367.
77. West L., Waldrop J., Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009, 23:75-89.
78. Whitaker-Azmitia P.M. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism?. Int J Dev Neurosci 2005, 23:75-83.
79. Zafeiriou D.I., Ververi A., Vargiami E. The serotonergic system: its role in pathogenesis and early developmental treatment of autism. Curr Neuropharmacol 2009, 7:150-157.